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Abstract
Background: Diabetes mellitus (DM) and hypertension (HTN) are accused of being responsible for the
development of the cardiac fibrosis due to severe cardiomyopathy.
Methods: Blood glucose (BG) test was carried out, lipid concentrations, tumor necrosis factor alpha (TNF-a),
transforming growth factor beta (TGF-b), matrix metalloproteinase (MMP-2), collagen-I and collagen-III were
measured in male Albino rats weighing 179-219 g. The rats were divided into five groups, kept on either control
diet or high fat diet (HFD), and simultaneously treated with rosiglitazone (PPAR-gamma) only for one group with
3 mg/kg/day via oral route for 30 days, and with rosiglitazone and felodipine combination for another group with
3 mg/kg/day and 5 mg/kg/day, respectively via oral route for 30 days.
Results: Diabetic hypertensive (DH) rats which fed on a HFD, injected with streptozotocin (STZ) (i.p.) and
obstruction for its right kidney was occurred develop hyperglycemia, hypertension, cardiac fibrosis,
hypertriglyceridemia, hypercholesterolemia, increased TNF-a, increased TGF-b, decreased MMP-2, increased
collagen-I and increased collagen-III, when compared to rats fed on control diet. Treating the DH rats with
rosiglitazone only causes a significant decrease for BG levels by 52.79%, triglycerides (TGs) by 24.05%, total
cholesterol (T-Chol) by 30.23%, low density lipoprotein cholesterol (LDL-C) by 40.53%, TNF-a by 20.81%, TGF-b by
46.54%, collagen-I by 48.11% and collagen-III by 53.85% but causes a significant increase for MMP-2 by 272.73%.
Moreover, Treating the DH rats with rosiglitazone and felodipine combination causes a significant decrease for BG
levels by 61.08%, blood pressure (BP) by 16.78%, TGs by 23.80%, T-Chol by 33.27%, LDL-C by 45.18%, TNF-a by
22.82%, TGF-b by 49.31%, collagen-I by 64.15% and collagen-III by 53.85% but causes a significant increase for
MMP-2 by 290.91%. Rosiglitazone alone failed to decrease the BP in DH rats in the current dosage and duration.
Conclusion: Our results indicate that the co-existence of diabetes and hypertension could induce cardiomyopathy
which could further result in cardiac fibrosis, and that combination treatment with rosiglitazone and felodipine has
a great protective role against the metabolic abnormalities, meanwhile, the treatment with rosiglitazone alone has
a protective role with a minimal effect against these abnormalities and has no effect on decreasing BP in these
cases which may lead to coronary artery diseases (CADs) in future.
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Diabetic cardiomyopathy, the leading cause of death in
diabetic patients, is characterized by both systolic and
diastolic dysfunction, due to reduced contractility, pro-
longed relaxation, and decreased compliance [1,2]. The
development of diabetic cardiomyopathy is multifactor-
ial. Putative mechanisms include metabolic disturbances,
small vessel disease, autonomic dysfunction, insulin
resistance, and myocardial fibrosis [3,4]. Recently inter-
stitial fibrosis has been regarded as an important patho-
genic factor of the heart’s impaired functional integrity
[5]; however, altered substrate supply and use by cardiac
myocytes could be the primary injury in the pathogen-
esis of this specific heart muscle disease. Structural and
functional impairment of myocytes, which occurs
already in the first week of diabetes, precedes cardiac
fibrosis and thus remains the key step in impairing con-
tractile performance, finally inducing heart failure [6].
T h ed i a g n o s i so fad i a b e t i cc a r d i o m y o p a t h yi sm a d ei n
patients in whom no other known etiological factors,
such as coronary artery disease, or hypertension, are
present [7].
Diabetes and high blood pressure are closely related
diseases. They occur together so frequently that they are
officially considered to be “comorbidities” (diseases likely
to be present in the same patient). Unfortunately, dia-
betes makes high blood pressure more difficult to treat,
and high blood pressure makes diabetes even more
dangerous [8].
Streptozotocin (STZ) is a naturally occurring, broad-
spectrum antibiotic [9]. Induction of experimental dia-
betes in the rat using STZ is very convenient and simple
to use but it is cyto-toxic chemical that is particularly
toxic to the pancreatic, insulin-producing beta cells in
mammals. STZ injection leads to the degeneration of
the Langerhans islets beta cells [10].
One class of insulin sensitizers of the invention is
Peroxisome Proliferator-Activated Receptors (PPAR)
modulators, and in particular PPAR-gamma modula-
tors, e.g., PPAR-gamma agonists. PPARs are members
of the nuclear hormone receptor superfamily of ligand-
activated transcription factors that are related to reti-
noid, steroid and thyroid hormone receptors. PPAR
modulators include the PPAR-alpha, PPAR-delta (also
called PPAR-beta), and PPAR-gamma agonists. Espe-
cially useful are the thiazolidinediones (TZDs), which
are exogenous substances, used for clinicians in dia-
betic patients and not expressed in any tissue. TZDs
act upon PPAR-gamma. PPAR-gamma are expressed in
many tissues especially the heart [11]. They were devel-
oped in the 70’sa n d8 0 ’s by screening newly synthe-
sized compounds for their ability to lower blood
glucose in diabetic rodents. Three molecules from this
class, troglitazone, rosiglitazone, and pioglitazone, were
ultimately approved for the treatment of patients with
type II diabetes [12].
Although these compounds were developed without
an understanding of their molecular mechanism of
action, by the early 90’s evidence began to accumulate
linking the thiazolidinediones to the nuclear receptor
PPAR-gamma. It was ultimately demonstrated that these
molecules were high affinity ligands of PPAR-gamma
and that they increased transcriptional activity of the
receptor. Ligands of PPAR-gamma including certain
thiazolidinediones, reduce myocardial tissue injury and
infarct size [13-15]. TZDs PPAR-gamma activators are
used clinically to improve insulin sensitivity and glyce-
mic control in patients with Type II diabetes. PPAR-
gamma is predominantly expressed in adipose tissue,
but is also expressed in myocardium [16]. The function
of PPAR-gamma in the heart suggests that activation of
myocardial PPAR-gamma may have metabolic and anti-
inflammatory effects. PPAR-gamma activation has been
shown to increase myocardial expression of glucose
transporters, promote carbohydrate substrate utilization
in cardiac myocytes and intact hearts [17,18], and
attenuate pro-inflammatory cytokine expression in acti-
vated cardiomyocytes [19], experimental myocarditis
[20] or chronic LV failure due to myocardial infarction
[21]. Moreover, most studies have shown that TZDs
PPAR-gamma activators reduce myocardial infarct size
and enhance recovery of contractile function in intact
rat hearts after ischemia and reperfusion. These findings
are derived from studies in both normal and insulin
resistant models [17,18,22,23].
Metabolic syndrome is associated with accelerated
macrovascular and microvascular coronary disease, car-
diomyopathy, and elevated inflammatory status [24-27].
Felodipine (which used as calcium channel blocker)
administration can attenuate the inflammatory and
fibrosis process. As felodipine is used for treating high
blood pressure. This medication helps to relax the blood
vessels, which improves blood flow and makes it easier
for the heart to pump blood. It has a direct beneficial
effect by inhibiting the nuclear translocation and DNA-
binding activity of nuclear factor-B, which plays a cen-
tral role in this process by regulating the expression of
several proinflammatory genes [28].
TNF-a is an acute phase reactive protein and a basic
medium of immunological regulation, and it is also an
inflammatory cytokine with pleiotropic biological effects.
In the circulatory system, TNF-a is responsible for
many myocardial diseases such as acute coronary syn-
drome [29], Acute myocardial infarction (AMI) [30,31],
myocarditis [32], dilated cardiomyopathy and congestive
heart failure (CHF) [33,34].
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lates collagen expression by stimulating extracellular
matrix synthesis, and mediates perivascular and myocar-
dial fibrosis. The increased gene expression of extracel-
lular matrix (ECM) components, such as collagen, and
of TGF-ß1 causes cardiac fibrosis and promotes cardiac
stiffness, leading to diastolic dysfunction [35].
Myocardial stunning was attenuated by inhibition of
MMP-2 activity [36,37]. In the setting of heart failure,
MMP-2 has been implicated in myocardial fibrosis,
increased myocardial stiffness and impaired contractility
of hearts from spontaneously hypertensive rats [38].
Cardiac fibroblasts are the most abundant cell type of
the myocardium and produce various proteins found in
ECM, including the major fibrillar collagens type I and
III, which comprise the bulk of the ECM, as well as col-
lagenases, fibronectin, and vitronectin [39].
Calcium channel blockers (CCBs) are widely used to
treat cardiovascular diseases [40].
In this study, we investigate the role of CCBs (felodi-
pine) and PPAR-gamma modulators on blood glucose
level, blood pressure, lipid profile, TNF-a,T G F - b1,
MMP-2, collagen-I and collagen-III in DH rats.
Materials and methods
Chemicals
Glucose (Spectrum Diagnostics, Cairo, Egypt). STZ
(Sigma chemical Company, Saint Louis, MO, USA).
Diet
T h ed i e tf o rf o r t yr a t sw e r ef e dah i g h - f a td i e tc o n s i s t s
of 22.5% hydrogenated vegetable oil, 22.5% milk powder,
51.5% soybean ground, 2% corn starch, 1% sucrose and
0.5% vitamins and minerals.
Animals
Fifty male Albino rats were used for the present study
after being procured from the animal house of El-Nile
Company for Pharmaceutical Products (Cairo, Egypt).
The animals were acclimatized for two weeks in the ani-
mal house of Zagazig University before dietary manipu-
lation. After two weeks of high-fat diet, induction of
diabetes was occurred, as rats were overnight fasted and
injected intra-peritoneal (i.p.) with 35 mg/kg STZ
(Sigma chemical Company, Saint Louis, MO, USA)
freshly prepared in cold 0.1 mol citrate buffer (pH 4.5)
[41]. One week after the injection of STZ hyperglycemic
state was first tested by detection of glucosuria using
urine glucose strips. Rats with two successive blood glu-
cose levels more than 300 mg/dl were used in this
study. Thus streptozotocin injury was occurred.
Then, induction of hypertension was occurred, as
thirty diabetic rats were anesthetized injection of sodium
thiopental (12 mg/100 gm) [42]. After anesthesia, the
animal was fixed in supine position on the operating
table and the abdominal skin was shaved and sterilized
with 70% ethyl alcohol. Then, a midline incision was
made, and the right renal artery was clamped for 45 min-
utes using a non-traumatic vascular clamp (Bulldog
clamp). Then, the edges of the abdominal incision were
approximated to each other and covered by a piece of
gauze soaked with warm isotonic saline (37°C) to pre-
vent undue loss of body fluids. Reperfusion achieved
after 15 minutes from removal of the vascular clamp on
the right renal artery [43].
Two rats were housed per wire floored cage in an air-
conditioned room (22 ± 2°C) with 12 h light/dark cycle
and had free access to standard laboratory chow diet (El
N a s rC o ,C a i r o ,E g y p t ) ,a n dw a t e rad libitum.T h ep r o -
tocol of the current study was approved by the depart-
ment of Biochemistry Council, Faculty of Pharmacy,
Zagazig University, which has an ethical authority.
Experimental design
Animals weighed 179-219 g at the time of dietary
manipulation. They were randomly assigned into five
groups of ten each, as given below:
i. Control group (C): Normal control healthy rats.
ii. Diabetic Control group (DC): Diabetic control
rats, that took fat diet for two weeks then injected
with STZ intraperitoneal (i.p.).
iii. Diabetic Hypertensive Control group (DHC):
Type 2 DM hypertensive rats, that took fat diet for
two weeks then injected with STZ i.p. Finally,
obstruction for right kidney was done for all of them
for induction of hypertension.
iv. DH rats + Rosiglitazone (R): Treated DH rats
with PPAR-gamma (Rosiglitazone) with a dose of
3 mg/kg/day [44] orally only for one month.
v. DH rats + combination of Rosiglitazone and Felo-
dipine (R+F): Treated DH rats with a combination
of PPAR-gamma (Rosiglitazone) with a dose of
3 mg/kg/day orally and CCB (Felodipine) with a
dose of 5 mg/kg/day [45] orally for one month.
The animals were maintained in their respective
groups for 30 days. Fasting serum glucose level, blood
pressure, lipid profile, TNF-a,T G F - b1, MMP-2,
collagen-I and collagen-III of all animals were measured
at the last day (day 30) of the experiment.
Blood Sample collection
Blood samples were collected from retro-orbital plexus
of the eye after 30 days from 12-h fasted rats into vacu-
tainer clotted tubes, where sera were obtained by centri-
fugation within 30 min at 4000 rpm at 4°C for 10 min
using Centurion centrifuge (K280R, UK), then divided
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profile and TNF-a while serum glucose was determined
immediately.
Harvesting of left ventricle specimen
The left ventricle of heart was removed rapidly and cut
into two equal halves by a scalpel. One half of it was
rapidly placed in 10% neutral buffered formalin for
immunostaining and the other half was rapidly frozen in
liquid nitrogen, and stored at -72°C for real time poly-
merase chain reactions (RT-PCR) assessments for TGF-
b1, MMP-2, collagen-I and collagen-III [46].
Histological examination
1) The selected paraffin blocks for immunohistochem-
ical staining were sectioned (4- μm thickness) and
stained with hematoxylin and eosin (H&E) stain [47].
2) Masson trichrome stain [48]: The data were
obtained using Leica Qwin 500 image analyzer computer
system (England). The image analyzer consisted of a
coloured video camera, coloured monitor, hard disc of
IBM personal computer connected to the microscope,
and controlled by Leica Qwin 500 software. The image
analyzer was first calibrated automatically to convert the
measument units (pixels) produced by the image analy-
zer program into actual micrometer units.
The area % of CT fibers was measured using an objec-
tive lens of magnification 10, i.e of a total magnification
of 100. Ten fields were measured for each specimen.
Using the colour detect, CT areas were masked by a
blue binary colour. The area % was calculated in relation
to a standard measuring frame of area 118476.6 micro-
meter square.
The data obtained were subjected to statistical analysis
using t-student’s test and ANOVA.
Biochemical measurements
The concentration of serum glucose was measured by
the enzymatic colorimetric GOD-POD procedure [49]
using Diamond Diagnostic kit (Germany).
Serum TGs were estimated by GPO-POD enzymatic
method [50] using a Biocon kit (India). T-Chol concen-
tration was determined utilizing enzymatic colorimetric
CHOD-PAP method [51] using Biocon kit (India). HDL-
C was determined by the same method after the precipi-
tation of very low density lipoprotein cholesterol
(VLDL-C) and LDL-C [52], and finally, LDL-C was cal-
culated by Using Friedewald’s Formula [53]:
LDL

mg/dl

=T C−

HDL − C+T A G / 5

.
Serum TNF-a w a sa s s e s s e db yt h er a tT N F -a l p h a
e n z y m e - l i n k e di m m u n o s o r b e n ta s s a y( E L I S A )k i tw h i c h
is an in vitro enzyme-linked immunosorbent assay for
the quantitative measurement of rat TNF- alpha cell
lysate and tissue lysate [54].
For the detection of collagen-I, collagen-III, TGF-b
and MMP-2 gene expression, RNA was extracted,
reverse transcribed into cDNA and amplified by PCR.
Total RNA was extracted from heart tissue using SV
Total RNA Isolation System (Promega, Madison, WI,
USA). The extracted RNA was reverse transcribed into
cDNA using RT-PCR kit (Stratagene, USA). Then
amplification of specific DNA sequences using two pri-
mers that hybridize to opposite strands and flank target
DNA region. At the end of the amplification process,
the DNA product was detected using agarose gel
electrophoresis.
Statistical analysis
The results were expressed as mean ± SD. To determine
the statistical significance of laboratory findings, multi-
ple comparisons were achieved using independent sam-
ples T- Test and ANOVA followed by Tukey test as
post hoc test. The correlations between BG and TNF-a
were tested by Pearson’s coefficient (r). P-value ≤ 0.05
was considered statistically significant.
Results
DC animals showed significant increase in their serum
glucose levels by 278.88% in comparison with group C.
Furthermore, DHC animals showed also significant
increase in their serum glucose levels by 35.15% in com-
parison with DC animals group. However, group R and
group R+F induced significant decrease in their serum
glucose levels by (52.79% and 61.08% respectively) in
comparison with DHC data (Table 1).
DC animals showed significant increase in their BP
levels by 25.52% in comparison with group C. Further-
more, DHC animals showed also significant increase in
their BP levels by 23.42% in comparison with DC ani-
mals group. But there is no significance between group
R and DHC data in its BP levels. However, group R+F
induced significant decrease in their BP levels by 16.78%
in comparison with DHC data (Table 1).
DC animals showed significant increase in their TGs
levels by 20.06% in comparison with group C. But, DHC
animals showed no significance in their TAG levels in
comparison with DC animals group. Meanwhile, there
was nearly the same significant decrease between group
R and group R+F in their TAG levels by (24.05% and
23.80% respectively) in comparison with DHC data
(Table 2).
DC animals showed a significant increase in their
T-Chol levels by 45.89% in comparison with group
C. Furthermore, DHC animals showed also a significant
increase in their T-Chol levels by 17.05% in comparison
with DC animals group. At the other side, there was a
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DHC group in their T-Chol levels by 30.23%. Also there
was a significant decrease between the group R+F in
their T-Chol levels by 33.27% in comparison with DHC
data (Table 2).
HDL-C levels decreased significantly in DC animals in
comparison with group C by a level of 20.93%. Also,
there was a significant decrease between DHC data in
their HDL-C levels by 6.92% in comparison with DC
data. Meanwhile, there was nearly the same significant
increase in group R and the group R+F levels by
(20.95% and 24.51% respectively) in comparison with
DHC data (Table 2).
LDL-C levels showed a significant increase in DC ani-
mals by 92.45% in comparison with group C. Also, there
was a significant increase in DHC animals in their LDL-
C levels by 24.9% in comparison with DC data. On the
other hand, LDL-C levels decreased significantly in
group R in comparison with DHC group by a level of
40.53%. Moreover, LDL-C levels decreased significantly
in the group R+F in comparison with DHC group by a
level of 45.18% (Table 2).
There is a significant increase in TNF-a level in DC
group by 22.59% in comparison with group C. Further-
more, DHC animals showed also significant rise in their
TNF-a levels by 10.23% in comparison with DC animals
group. However, group R and group R+F induced nearly
the same significant decrease in their TNF-a level by
(20.81% and 22.82% respectively) in comparison with
DHC data (Table 2, Figure 1).
TGF-b levels showed a significant rise in DC group by
89.62% in comparison with group C. But, DHC group
showed no significance in their TGF-b levels in compar-
ison with DC group. However, group R and group R+F
induced nearly the same significant decrease in their
TGF-b levels by (46.54% and 49.31% respectively) in
comparison with DHC group data (Table 2, Figure 2).
MMP-2 levels DC showed a significant decrease in DC
group by 92.68% in comparison with group C. But, DHC
group showed a significant rise in their MMP-2 levels by
Table 1 Effect of STZ and obstruction for right kidney on fasting serum glucose and blood pressure
Groups
Control Diabetic Control Diabetic Hypertensive Control Rosiglitazone Rosiglitazone+Felodipine
Glucose (mg/dL) 98.00 ± 9.61 371.30 ± 39.09 ^ 501.80 ± 54.44* 236.90 ± 47.98# 195.30 ± 47.35#
Blood Pressure (mmHg) 126.20 ± 4.78 158.40 ± 14.09^ 195.50 ± 13.26* 189.90 ± 13.16 162.70 ± 16.73#a
Values are expressed as mean ± SD. Number of rats per group n = 10.
STZ, streptozotocin.
^ Significant difference from normal control at P < 0.05.
* Significant difference from diabetic control at P < 0.05.
# Significant difference from diabetic hypertensive control at P < 0.05.
a Means of treated groups with different superscript are significantly different from each other at P < 0.05.
Table 2 Measurements of fasting serum lipids, TNF-a, TGF-b, MMP-2, collagen-I, collagen-III and masson trichrome
Groups
Control Diabetic Control Diabetic Hypertensive Control Rosiglitazone Rosiglitazone + Felodipine
TGs (mg/dL) 79.50 ± 2.65 95.45 ± 6.38^ 98.95 ± 7.29 75.15 ± 4.94# 75.40 ± 7.31#
T-Chol (mg/dL) 133.38 ± 7.17 194.59 ± 14.36^ 227.76 ± 19.94* 158.90 ± 6.82# 151.98 ± 6.83#a
LDL-C (mg/dL) 72.86 ± 9.39 140.22 ± 14.91^ 175.13 ± 19.69* 104.15 ± 7.64# 96.01 ± 8.08#a
HDL-C (mg/dL) 44.62 ± 3.62 35.28 ± 2.22^ 32.84 ± 1.62* 39.72 ± 2.47# 40.89 ± 2.77#
TNF-a (ng/mL) 203.19 ± 10.88 249.10 ± 13.73^ 274.58 ± 17.38* 217.45 ± 18.23# 211.93 ± 17.91#
TGF-b 1.06 ± 0.09 2.01 ± 0.23^ 2.17 ± 0.29 1.16 ± 0.10# 1.10 ± 0.07#
MMP-2 0.82 ± 0.09 0.06 ± 0.04^ 0.11 ± 0.05* 0.41 ± 0.12# 0.43 ± 0.22#
Collagen-I 0.11 ± 0.04 0.80 ± 0.21^ 1.06 ± 0.27* 0.55 ± 0.09# 0.38 ± 0.11#a
Collagen-III 0.06 ± 0.02 0.11 ± 0.03^ 0.13 ± 0.06 0.06 ± 0.02# 0.06 ± 0.02#
Masson trichrome 13.54 ± 1.31 10.79 ± 1.86^ 22.34 ± 6.29* 8.79 ± 1.44# 10.45 ± 2.96#
Values are expressed as mean ± SD. Number of rats per group n = 10.
STZ, streptozotocin; TGs, triglycerides; T-Chol, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TNF-a,
tumor necrosis factor alpha; TGF-b, transforming growth factor beta; MMP-2, matrix metalloproteinase-2.
^ Significant difference from normal control at P ≤ 0.05.
* Significant difference from diabetic control at P ≤ 0.05.
# Significant difference from diabetic hypertensive control at P ≤ 0.05.
a Means of treated groups with different superscript are significantly different from each other at P ≤ 0.05.
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R and group R+F data induced nearly the same signifi-
cant rise in their MMP-2 levels by (272.73% and
290.91% respectively) in comparison with DHC group
data (Table 2, Figure 3).
Our results revealed that, there is no significant differ-
ence between TGF-b and MMP-2
There was a significant rise in their collagen I levels in
DC group by 627.27% in comparison with group C.
Furthermore, DHC animals showed also significant rise
in their collagen I levels by 32.50% in comparison with
DC animals group. However, group R induced a signifi-
cant decrease in their collagen I levels by 48.11% in
comparison with DHC data group. Also, group R+F
induced a significant decrease in their collagen I levels
by 64.15% in comparison with DHC data group (Table
2, Figure 4).
There was a significant rise in their collagen III levels
in DC group by 83.33% in comparison with group C.
But, DHC group showed no significance in their
collagen III levels in comparison with DC animals
group. However, group R and group R+F induced the
same significant decrease in their collagen III levels by
nearly 53.85% in comparison with DHC data group
(Table 2, Figure 5).
Light microscope examination of H&E stained sec-
tions of the cardiac muscle of the group C rats revealed
that the cardiac muscle fibers are connected end to end
by intercalated discs appeared with central and oval vas-
cular nuclei.
H&E stained sections of the cardiac muscle of the DC
group rats showed degeneration in some of the cardiac
muscle fibers in the form of separation and fragmenta-
tion of the cardiac muscle fibers.
Examination of H&E stained sections of the cardiac
muscle of the DHC group rats showed longitudinal sec-
tion in the cardiac muscle fibers showing hypertrophy of
the cardiomyocytes.
The cardiac muscle fibers of rats receiving rosiglita-
zone treatment alone showedm i l df r a g m e n t a t i o na n d
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Figure 1 Percentage change of TNF-a in group DC; group
DHC; group R and group R+F for one month. Each value is
expressed in ng/mL. (^) Significant difference from normal control
at P < 0.05. (*) Significant difference from diabetic control at P <
0.05. (#) Significant difference from diabetic hypertensive control at
P < 0.05. Using one way ANOVA followed by Tukey test as post hoc
test.
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Figure 2 Percentage change of TGF-b in group DC; group DHC;
group R and group R+F for one month. (^) Significant difference
from normal control at P < 0.05. (#) Significant difference from
diabetic hypertensive control at P < 0.05. Using one way ANOVA
followed by Tukey test as post hoc test.
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Figure 3 Percentage change of MMP-2 in group DC; group
DHC; group R and group R+F for one month. (^) Significant
difference from normal control at P < 0.05. (*) Significant difference
from diabetic control at P < 0.05. (#) Significant difference from
diabetic hypertensive control at P < 0.05. Using one way ANOVA
followed by Tukey test as post hoc test.
                                                      Collagen-I  
DC
DHC
R
R+F
-200
0
200
400
600
800 ^
#
Groups
*
#a
P
e
r
c
e
n
t
a
g
e
Figure 4 Percentage change of collagen-I in group DC; group
DHC; group R and group R+F for one month. (^) Significant
difference from normal control at P < 0.05. (*) Significant difference
from diabetic control at P < 0.05. (#) Significant difference from
diabetic hypertensive control at P < 0.05. a....., Means of treated
groups with different superscript are significantly different from
each other at P < 0.05. Using one way ANOVA followed by Tukey
test as post hoc test.
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sections.
Histological examination ofH & Es t a i n e ds e c t i o n so f
the cardiac muscle fibers of rats receiving combined
treatment of rosiglitazone and felodipine revealed a
nearly normal appearance of the cardiac muscle fibers
with no fosi of degeneration.
Our results illustrated that, there was a significant
decrease in their area percentage of masson trichrome
stained connective tissue (CT) fibers of cardiac muscle
levels in DC group by 20.285% in comparison with
group C. Meanwhile, DHC rats showed a significant
increase in their area percentage of masson trichrome
stained CT fibers levels by 106.975% in comparison with
DC rats group. However, group R induced a significant
decrease in their area percentage of masson trichrome
stained CT fibers levels by 60.67% in comparison with
DHC data group. Also, group R+F induced a significant
decrease in their area percentage of masson trichrome
stained CT fibers levels by 53.24% in comparison with
DHC data group. Moreover, there is no significant dif-
ference between R group and R+F group rats (Table 2,
Figure 6).
Discussion
Diabetes is a growing global health problem with type 2
DM being now an epidemic [55]. The major clinical
consequences of type 2 DM are mortality and morbidity
from vascular complications [56]. Moreover patients
with type 2 DM have an increased risk of premature
development and accelerated progression of athero-
sclerosis [57].
The pathogenesis of CVD in DM is multi-factorial and
can be affected by many factors such as hyperglycemia,
increased production of fatty acids, and altered
lipoproteins [58]. Recently, important factors were pro-
posed to initiate CV complications in type 2 DM,
including cardiac fibrosis and inflammation [59]. Conse-
quently, there have been considerable recent efforts to
focus on non-traditional risk factors for CV events in
type 2 DM patients’ population.
Streptozotocin (STZ) is a synthetic antineoplastic
agent that is classifically an anti-tumor antibiotic and
chemically is related to other nitrosureas used in cancer
chemotherapy. STZ injury, induced diabetes can begin
an autoimmune process that results in destruction of
the Langerhans islets beta cells and toxicity of beta cells
of pancreas with emergence of clinical diabetes within
2-4 days [60].
The result of our study explained that, in STZ-
induced diabetic and DH groups when compared to the
normal control healthy group, there was a significant
increase in BG. This result was consistent with many
studies [60-63].
Our study explained that, there was a significant
increase in BG levels between DC and DHC rats (group
II and III, respectively) compared with group C. Also
this is supported by a significant positive correlation
between BG and BP. This study is confirmed with the
study of [64].
In the contrary, rosiglitazone showed a significant
decrease in BG levels in treated groups (groups R and R
+F, respectively). But there is no significantly decrease
in group R+F which is treated with rosiglitazone and
felodipine combination in comparison to group R which
is treated with rosiglitazoneo n l y .T h i ss t u d yi sc o n s i s -
tent with [62].
From these data, it is clear that rosiglitazone which
acts as peroxisome proliferator activated receptor
gamma had the greatest role in treatment of DM. But at
the other hand, there was no role for felodipine in
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Figure 5 Percentage change of collagen-III in group DC; group
DHC; group R and group R+F for one month. (^) Significant
difference from normal control at P < 0.05. (*) Significant difference
from diabetic control at P < 0.05. (#) Significant difference from
diabetic hypertensive control at P < 0.05. Using one way ANOVA
followed by Tukey test as post hoc test.
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Figure 6 Percentage change of masson trichrome in group DC;
group DHC; group R and group R+F for one month. (^)
Significant difference from normal control at P < 0.05. (*) Significant
difference from diabetic control at P < 0.05. (#) Significant difference
from diabetic hypertensive control at P < 0.05. Using one way
ANOVA followed by Tukey test as post hoc test.
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Page 7 of 12treatment of DM, so there is no significant decrease in
BG when felodipine was added to treatment.
Hypertension is a major risk factor for CHD and can
induce several other risk factors [65]. Hence, regarding
the blood pressure; BP was elevated in the DC and
DHC rats (groups II and III, respectively) compared
with group C. This was also the case in the studies con-
ducted on hypertensive type 2 DM patients [66].
Furthermore, this is supported by a positive correlation
between BG and BP.
In the contrary, there is a significant decrease in group
V which is treated with rosiglitazone and felodipine
combination due to felodipine effect in comparison to
DHC rats (group III). But on the other hand, there is
no significant decrease in group R which is treated
w i t hr o s i g l i t a z o n eo n l yi nc o m p a r i s o nt oD H Cr a t s
(group III).
From these data, it is obvious that treatment combina-
tion of rosiglitazone and felodipine had the upper hand
in decreasing BP over rosiglitazone treatment only
because of the role of felodipine which acts as calcium
channel blocker [67].
It is reported that prolonged exposure to hyperglycemia
is recognized as the primary casual factor in the pathogen-
esis of diabetic cardiac complications. Even in the upper
limits of normal range and independent of other known
risk factors, hypertension could be predictor of coronary
events [68,69]. These findings confirm that hyperglycemia
induces a large number of alterations in the cardiac tissue
that potentially promote increasing of interstitial fibrosis
and myocyte apoptosis [70,71]. Several studies have
attempted to find the link between hyperglycemia
and development of coronary atherosclerosis [72,73].
Therefore, the highest BG and BP values were observed in
DHC group.
We should be aware of the important relationship
between type 2 DM and cardiac fibrosis.
Hence, the present study was conducted aiming to
evaluate the role of lipid profile, TNF- a,T G F - b,C o l -
lagen I, Collagen III and MMP-2 in type 2 DM hyper-
tensive patients who developed cardiac fibrosis.
Correlating these parameters in the DHC groups, as
well as their relation with glycemic status was also a tar-
get in this study. In order to achieve our aim, we
assessed the levels of these biochemical markers in
DHC rats with and without cardiac fibrosis and com-
pared them with group C. This was done in an attempt
to explore the possible relationships between hypergly-
cemia, hypertension, dyslipidemia and inflammation as
well as cardiac fibrosis.
It was stated that dyslipidemia is a recognized risk fac-
tor for CVD in DM. In our study, all diabetic rats
showed significant dyslipidemia compared with the
healthy control subjects. It was found that the levels of
TAG, T-Chol, and LDL-C were significantly increased
in DC and DHC groups (II and III, respectively) as com-
pared to the group C. On the other hand, the level of
HDL-C was significantly reduced in both groups, as
compared to the group C. Furthermore, this fact is sup-
ported with a significant positive correlation between
BG and T- Chol [74].
In the contrary, there was a significant increase for
HDL-C in group R which was treated with rosiglitazone
only and group R+F which was treated with combina-
tion of rosiglitazone and felodipine in comparison to
DHC rats. But there was no significant difference
between group R+F and group R. It is obvious that
there is no great role for felodipine in increasing HDL-C
for DH rats.
Furthermore, there was a significant increase for
T-Chol in DC and DHC groups (II and III, respectively).
But, there was a significant decrease for T-Chol in
group R which was treated wit hr o s i g l i t a z o n eo n l ya n d
group R+F which was treated with combination of rosi-
glitazone and felodipine in comparison to DH rats. And
also, there is a significant decrease for T-Chol in group
R and R+F.
The work was reported that; when raised TAG co-
exists with an atherogenic T-Chol profile, the overall
risk of atherosclerosis is enhanced. The more features of
metabolic syndrome; a rat has the greater the risk which
is made much worse by concomitant LDL-C elevation
[75,76].
Hyperglycemia may be associated with proatherogenic
modifications to plasma lipoproteins [77]. TNF-a is one
of the key inflammatory mediators expressed during a
variety of inflammatory conditions, and takes part in a
variety of physiological and pathological phenomena as
increasing of its expression in coronary arteries [78].
In our study, there was a significant increase in DC
and DHC rats groups (II and III, respectively) as com-
pared with group C. Also there was a significant
decrease for TNF-a in group R which was treated with
rosiglitazone only and in group R+F which was treated
with combination of rosiglitazone and felodipine in
comparison to DHC rats. Furthermore there was no sig-
nificant difference between group R and R+F.
These findings confirm that felodipine has no any role
in improvement of TNF-a expression in cardiac fibrosis
cases. So it is obvious that there is a potent relation
between increasing of TNF-a expression and (CADs)
[79]. Also, this is supported with a significant positive
correlation between BG and TNF-alpha.
The myocardium is composed of cardiac myocytes
enveloped in a dense extracellular network of collagen,
the main structural protein. Cardiac myocytes account
for 70% to 75% of the myocardium by cell volume but
only 25% to 30% by cell number [80].
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the myocardium and produce various proteins found in
the extracellular matrix (ECM), including the major
fibrillar collagens type I and III, which comprise the
bulk of the ECM, as well as collagenases, fibronectin,
and vitronectin [81].
Our study explained that, there was a significant
increase for collagen I in DC and DHC rats groups
(II and III, respectively) in comparison to group C
(group I).
On the other hand, there was a significant decrease in
group R which was treated wit hr o s i g l i t a z o n eo n l ya n d
group R+F which was treated with rosiglitazone and
felodipine combination in comparison to DHC rats
(group III).
Furthermore, there was a significant decrease within
groups (R and R+F), this elucidates that group R+F
which was treated with rosiglitazone and felodipine
combination is more potent action on collagen I than
group R which was treated with rosiglitazone only.
These findings confirm that the treatment with combi-
nation of rosiglitazone and felodipine has the upper
hand on treatment with rosiglitazone alone which clarify
that, this combination has a great role on attenuating
cardiac perivascular fibrosis due to the presence of felo-
dipine which acts as calcium channel blocker due to the
blood pressure regulation. And also, there was a signifi-
cant increase for collagen III in DC and DHC rats in
groups (II and III, respectively) in comparison to group
C (group I). But there was no significant difference
within groups (DC and DHC). But, there was a signifi-
cant decrease in group R which was treated with rosigli-
tazone only and in group R+F which was treated with
rosiglitazone and felodipine combination when com-
pared with DHC rats (group III). It is obvious that,
there was no significantly difference between group R
and group R+F. It is confirmed that there was no corre-
lation between blood glucose and collagen III, but there
was a positive correlation between BP and collagen III.
So it is cleared that the addition of felodipine to treat-
ment has no effect on improvement of collagen III. This
result is opposed with the study of [40].
TGF-b is a multifunctional cytokine that acts on a
wide assortment of cell types regulating both cell growth
and differentiation. TGF-b can have potent inhibitory
effects on T-cell proliferation, cytokine production, and
cytolytic functions [82].
Our study showed a significant increase of TGF-b in
DC and DHC rats in groups (II and III, respectively) in
comparison to group C (group I). But, there was no sig-
nificantly difference between groups (DC and DHC).
On the other hand, there was a significant decrease in
group R which was treated wit hr o s i g l i t a z o n eo n l ya n d
group R+F which was treated with rosiglitazone and
felodipine combination in comparison to DHC rats
(group III). But, at the same time, there was no signifi-
cantly difference between groups (R and R+F).
It is clear that, the results of TGF-b clarified that trea-
ted groups even with rosiglitazone only (group R) or
with rosiglitazone and felodipine combination (group R
+F) are nearly near to group C (group I). The conclu-
sion for TGF-b shows that it is a very good indicator for
determination of cardiac fibrosis as TGF-b1 is produced
normally at low levels in cardiac tissue. However, when
myocardial injury occurs, TGF-b1 is released in large
quantities by injured myocytes, fibroblasts, infiltrating
macrophages and lymphocytes. [83] is consistent with
our study.
MMPs are an endogenous family of proteolytic
enzymes that play an important role in extracellular
matrix (ECM) turnover and cardiac remodeling. The
MMP family consists to date of more than 20 species
including collagenases (such as MMP-1 and MMP-13),
gelatinases (such as MMP-2 and MMP-9), stromelysin
(MMP-3) and membranous type MMP (such as MT1-
MMP). MMP-2 is produced by cardiomyocytes, cardiac
fibroblasts and endocardial cells. Alterations in the
expression and activity of MMP-2 have been demon-
strated in a number of pathophysiological conditions.
As increased MMP-2 expression should result in a
decreased level of cardiac interstitial collagen, in which
large increases in gelatinase activity were associated
with increased total collagen content. In the setting of
myocardial ischemia/reperfusion, acutely elevated
MMP-2 activity contributes to myocardial stunning in
human and rat hearts, independent of an effect on the
ECM. During post-ischemic reperfusion, activation of
intracellular MMP-2 leads to cleavage of the contractile
regulatory protein troponin-I. Conversely, myocardial
stunning was attenuated by inhibition of MMP-2 activ-
ity [37,84-86].
In our study, low MMP-2 level was clearly observed in
type 2 DM and DH rats, which is consistent with the
study of [85] who stated that MMP-2 is a good indicator
for evaluating cardiac fibrosis in degenerative diseases
like DM. The decreased MMP-2 significant level
observed in our DC and DHC rat groups (II and III,
respectively) when compared to group C.
But, on the other hand, there was a significant
increase in group R which was treated with rosiglitazone
only and in group R+F which was treated with rosiglita-
zone and felodipine combination in comparison to DHC
rats group. Also, at the same time, there was no signifi-
cant difference between groups R and R+F. This is sup-
ported by a positive correlation between BG and MMP-2.
[87] is also consistent with this study.
It is obvious that, there is no significant difference
between TGF-b and MMP-2.
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stained CT fibers of treated groups were nearly the
same as control healthy group that have excellent results
than that of DHC group rats, which emphasize the great
role of rosiglitazone and felodipine treatment in attenu-
ating the cardiac fibrosis.
Conclusion
Our study revealed that DH rats develop hyperglycemia,
hypertension and cardiac fibrosis. They also resulted in
metabolic dyslipidemia, increased TNF-a,T G F - b,c o l -
lagen-I and collagen-III and decreased MMP-2. Our
results demonstrate that treatment with rosiglitazone
alone is able to improve the hyperglycemia, dyslipide-
mia, and to decrease TNF-a, TGF-b, collagen-I and col-
lagen-III and increased MMP-2 but within a minimal
effect. Meanwhile, it had no effect on attenuating the
hypertension which may lead to CADs again. Moreover,
the combined treatment with rosiglitazone and felodi-
pine is able to improve the hyperglycemia and has a
great effect on attenuating the hypertension. The com-
bined treatment is also able to improve dyslipidemia,
and to decrease TNF-a, TGF-b, collagen-I and collagen-
III and increased MMP-2 but within a greater effect
than treatment with rosiglitazone alone.
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